Curia, a contract research, development and manufacturing organization, agreed to acquire LakePharma, a provider of biologics services intended to serve pharmaceutical and biotechnology markets. Financial terms were not disclosed. "LakePharma will expand our integrated approach to provide biotech and pharmaceutical companies with small and large molecule research, development and manufacturing solutions. Funding and innovation in the biotech sector remains strong. Our combined capabilities will enable us to partner with our customers by seamlessly providing LakePharma's multi-modality innovation and speed along with fill-finish solutions from Curia. Our agreements with LakePharma and Integrity Bio demonstrate our commitment to expanding and deepening our biologics capabilities to help our customers advance from curiosity to cure," John Ratliff, Curia Chairman & CEO.